BR112021017239A2 - Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas - Google Patents

Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas

Info

Publication number
BR112021017239A2
BR112021017239A2 BR112021017239A BR112021017239A BR112021017239A2 BR 112021017239 A2 BR112021017239 A2 BR 112021017239A2 BR 112021017239 A BR112021017239 A BR 112021017239A BR 112021017239 A BR112021017239 A BR 112021017239A BR 112021017239 A2 BR112021017239 A2 BR 112021017239A2
Authority
BR
Brazil
Prior art keywords
derivatives
vaccines
conjugated
carbocyclic
oligomers
Prior art date
Application number
BR112021017239A
Other languages
English (en)
Inventor
Francesco Berti
Luigi Lay
Paolo Costantino
Roberto Adamo
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112021017239A2 publication Critical patent/BR112021017239A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas. a presente invenção está no campo das vacinas e refere-se a oligômeros tendo um grau selecionado de polimerização, obtido ao se conectar em conjunto várias unidades de repetição carbocíclicas, e aos derivados conjugados dos mesmos. os oligômeros e derivados conjugados dos mesmos da invenção também têm um grau selecionado de acetilação. os derivados da invenção são úteis para a preparação de composições imunogênicas, por exemplo, na forma de uma vacina.
BR112021017239A 2019-03-08 2020-03-06 Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas BR112021017239A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19161716 2019-03-08
PCT/EP2020/055950 WO2020182635A1 (en) 2019-03-08 2020-03-06 Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines

Publications (1)

Publication Number Publication Date
BR112021017239A2 true BR112021017239A2 (pt) 2021-11-09

Family

ID=66000932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017239A BR112021017239A2 (pt) 2019-03-08 2020-03-06 Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas

Country Status (8)

Country Link
US (1) US20220152183A1 (pt)
EP (1) EP3934696A1 (pt)
JP (1) JP2022523570A (pt)
CN (1) CN114126662A (pt)
BR (1) BR112021017239A2 (pt)
CA (1) CA3131741A1 (pt)
MX (1) MX2021010555A (pt)
WO (1) WO2020182635A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0409750D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Integration of meningococcal conjugate vaccination
BR112016019735A2 (pt) 2014-02-28 2017-10-17 Glaxosmithkline Biologicals Sa fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica

Also Published As

Publication number Publication date
CN114126662A (zh) 2022-03-01
JP2022523570A (ja) 2022-04-25
US20220152183A1 (en) 2022-05-19
EP3934696A1 (en) 2022-01-12
WO2020182635A1 (en) 2020-09-17
MX2021010555A (es) 2022-04-06
CA3131741A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
BR112019006278A2 (pt) composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
PE20230767A1 (es) Redireccion del tropismo de las capsides de aav
CO2017010191A2 (es) Éteres de celulosa esterificados solubles en agua que tienen grado bajo de neutralización
BR112018012873A2 (pt) vacina de vírus zika
BR112017018367A2 (pt) gelificação de éteres de celulose esterificados
BR112012022800A2 (pt) composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
BR112015028414A2 (pt) composição farmacêutica de micela de polímero
BR112021017239A2 (pt) Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
CU20200036A7 (es) Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BR112014027620A2 (pt) formulação, uso de uma formulação, processo para fabricar uma formulação, composto, e, processo para a preparação de um composto
BR112018001978A2 (pt) composição farmacêutica compreendendo fibras obtidas de forma eletro-hidrodinâ¬mica, composição com tempo de permanência melhorado sobre o local de aplicação
AR105098A1 (es) Soporte polimérico adhesivo hemostático altamente eficaz
BR112022024045A2 (pt) Moduladores il-17a
BR112018004538A2 (pt) processo para produção de pelo menos um de fibra celulósica, arabinoxilano solúvel em água, arabinoxilano ramificado de baixo peso molecular ou arabinoxilano de baixo peso molecular, uso de uma composição, ingrediente, composição, e, fibra
BR112015023738A2 (pt) vacinas de nucleoproteina influenza
CO2023015036A2 (es) Composición inmunogénica contra la influenza
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
BR112018072741A2 (pt) método para a profilaxia de infecção pelo vírus da zika
UY39428A (es) Composiciones de vacunas multivalentes y usos de las mismas